title: Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease.
abstract: BACKGROUND
  The prognosis associated with metabolic syndrome and high-sensitivity C-reactive protein (hs-CRP) in patients with stable coronary artery disease has not been well established.
  
  
  METHODS
  The WIZARD study was to determine the effects of 12 weeks of antibiotic therapy on coronary heart disease events in patients with stable coronary artery disease and known Chlamydia pneumoniae exposure. Baseline metabolic risk factors were available for 3319 patients enrolled from 1997 to 1998. The primary outcome was the first occurrence of death, recurrent myocardial infarction, coronary revascularization procedure, or hospitalization for angina.
  
  
  RESULTS
  Of the 3319 subjects, 825 patients experienced the primary outcome during the mean follow-up of 37 months. For the composite outcome, there was an increased hazard ratio (HR) for metabolic syndrome (HR 1.40, 95% CI 1.22-1.61) (unadjusted) and for hs-CRP (HR 1.60, 95% CI 1.38-1.85) (unadjusted). Both the metabolic syndrome and hs-CRP indicated, in a multivariable model including age and sex, an increased HR for the primary outcome (metabolic syndrome: HR 1.33, 95% CI 1.15-1.53; hs-CRP: HR 1.52, 95% CI 1.30-1.76).
  
  
  CONCLUSIONS
  Although related, the presence of the metabolic syndrome and increased levels of hs-CRP were associated with increased risk of adverse cardiovascular outcomes.
authors.affiliation: Cardiology Division, Baylor College of Medicine, Houston, TX 77030, USA. daguilar@bcm.edu
authors.forename: David
authors.initials: D
authors.lastname: Aguilar
authors.forename: Marian R
authors.initials: MR
authors.lastname: Fisher
authors.forename: Christopher M
authors.initials: CM
authors.lastname: O'Connor
authors.forename: Michael W
authors.initials: MW
authors.lastname: Dunne
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Muhlestein
authors.forename: Louis
authors.initials: L
authors.lastname: Yao
authors.forename: Sandeep
authors.initials: S
authors.lastname: Gupta
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Benner
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Cook
authors.forename: Dearborn
authors.initials: D
authors.lastname: Edwards
authors.forename: Marc A
authors.initials: MA
authors.lastname: Pfeffer
mesh_terms: D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis*; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000453:epidemiology*; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000453:epidemiology; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000453:epidemiology*; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D014280:Triglycerides; D002097:C-Reactive Protein